Total for the last 12 months
number of access : ?
number of downloads : ?
ID 118462
Title Alternative
Genomewide methylation profiling identifies a novel gene signature for patients with synchronous colorectal cancer
Methylation signature for synchronous CRC
Author
Okada, Yasuyuki Beckman Research Institute of City of Hope|Tokushima University Tokushima University Educator and Researcher Directory
Peng, Fuduan University of California Irvine
Perea, José Fundación Jiménez Díaz University Hospital
Corchete, Luis University Hospital of Salamanca|Institute of Biomedical Research of Salamanca|Cancer Research Center|Center for Biomedical Research in Network of Cancer
Bujanda, Luis Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas|Universidad del País Vasco
Li, Wei University of California Irvine
Goel, Ajay Beckman Research Institute of City of Hope|City of Hope Comprehensive Cancer Center
Keywords
synchronous colorectal cancer
gene methylation
predictive biomarker
Content Type
Journal Article
Description
Background: There are no robust tools for the diagnosis of synchronous colorectal cancer (SyCRC). Herein, we developed the first methylation signature to identify and characterize patients with SyCRC.
Methods: For biomarker discovery, we analyzed the genome-wide methylation profiles of 16 SyCRC and 18 solitary colorectal cancer (SoCRC) specimens. We thereafter established a methylation signature risk-scoring model to identify SyCRC in an independent cohort of 38 SyCRC and 42 SoCRC patients. In addition, we evaluated the prognostic value of the identified methylation profile.
Results: We identified six differentially methylated CpG probes/sites that distinguished SyCRC from SoCRC. In the validation cohort, we developed a methylation panel that identified patients with SyCRC from not only larger tumor (AUC=0.91) but also the paired remaining tumor (AUC=0.93). Moreover, high risk scores of our panel were associated with the development of metachronous CRC among patients with SyCRC (AUC=0.87) and emerged as an independent predictor for relapse-free survival (hazard ratio=2.72; 95% CI=1.12–6.61). Furthermore, the risk stratification model which combined with clinical risk factors was a diagnostic predictor of recurrence (AUC=0.90).
Conclusions: Our novel six-gene methylation panel robustly identifies patients with SyCRC, which has the clinical potential to improve the diagnosis and management of patients with CRC.
Journal Title
British Journal of Cancer
ISSN
00070920
15321827
NCID
AA00574355
Publisher
Springer Nature
Volume
128
Issue
1
Start Page
112
End Page
120
Published Date
2022-11-01
Remark
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use (https://www.springernature.com/gp/open-research/policies/accepted-manuscript-terms), but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1038/s41416-022-02033-9
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Author
departments
University Hospital